Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 3/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28716072 | 0.89 | PDE4A (0.33) | HTR1AADRA2AADRA2BADRA2CSLC6A2 | |
| SCHEMBL899973 | 0.82 | DRD1 (0.35) | KMT2ADRD1 | |
| SCHEMBL28813439 | 0.80 | PDE4B (0.41) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16467697 | 0.79 | MCHR1 (0.34) | HTR1AADRA2AADRA2BADRA2CSLC6A2 | |
| SCHEMBL1067817 | 0.77 | CA1 (0.38) | ADRA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15352714 | 0.77 | HTR1A (0.35) | HTR1AADRA2AADRA2BADRA2CSLC6A2 | |
| SCHEMBL15353343 | 0.75 | SLC6A2 (0.42) | HTR1AADRA2AADRA2BADRA2CSLC6A2 | |
| SCHEMBL1063855 | 0.75 | KCNK3 (0.30) | — | |
| SCHEMBL2469198 | 0.73 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DMCHR1 | |
| SCHEMBL27880771 | 0.72 | PDE4B (0.43) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013347-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013347-A1 | Tri-aryl-substituted-ethane PDE4 inhibitors | PDE4A, PDE4B, PDE3A | HTR1A 1173/4885ADRA2A 397/4885ADRA2B 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.